Evaluating Edge-to-edge Transcatheter Tricuspid Valve Repair in Patients With Severe Symptomatic Tricuspid Regurgitation

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.

Also called NCT05628779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05628779
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT05628779. Randomized; no masking; primary purpose treatment. Start 2022-12-12 (actual); primary completion 2027-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating Edge-to-edge Transcatheter Tricuspid Valve Repair in Patients With Severe Symptomatic Tricuspid Regurgitation
Acronym
TRACE-NL
Condition
Tricuspid Valve Regurgitation, Nonrheumatic
Condition
Heart Failure, Right Sided
Condition
Valve Regurgitation, Tricuspid
Intervention (Device)
TriClip TTVr system (Abbott Vascular)
Intervention (Device)
PASCAL TTVr system (Edwards Lifesciences)
Lead sponsor
St. Antonius Hospital (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)

Record details

Record id
cardio:ct-nct05628779
Content hash
68cad7f8a2a53d5bd8498c8bc8f86d12606e650222529851327afd9ee0f469f9